Esta semana se informaron novedades importantes con respecto a la vacuna argentina contra el COVID-19. El equipo de investigación ya completó el ensayo clínico de fase 3 y presentará la información a la Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT).
The organization will continue with the process and the next steps will be the eventual approval of the vaccine.
El Plan de Digitalización está cerrando todas las brechas de género y edad
PAMI beneficiaries for retirees and retirees: the release that is key for all our affiliates
“This is a concrete step and has some effects, such as for us to have this assembly and notice the presence of ANMAT,” confided the Minister of Health of the Nation, Carla Vizzotti.
Then, find out about the aptitude card, complete the basic times for phase 3 and provide this data to the ANMAT to continue with the evaluation procedure for your possible registration.
At the moment there are no specific moments or tasks, progress is made at the pace of the company.
This week, Vizzotti organizes an assembly with his science, generation and innovation colleagues, Daniel Filmus, and the president of the National Agency for the Promotion of Research, Technological Development and Innovation (I D i Agency), Fernando Peirano, with the researcher Apparatus for clinical research on ARVAC vaccination Phase 3 Cecilia Grierson.
It works on the stages of the regulatory path, which are explained through ANMAT, and discusses the option of presenting vaccines to the Pan American Health Organization (PAHO) for evaluation in prequalification. This is expected in a horizon of access to the revolving fund, “hand in hand with imaginable methods for the export of the vaccine to other countries in the region,” the aptitude map indicates.
Vizzotti was, in this sense, the one who wants to “address other types of paintings and the next steps to follow to identify a not unusual strategy and collaborate as much as possible. ” Furthermore, the minister stressed the importance of “this initiative as the first step towards a large-scale policy”, in “hour-long driving mode to continue the creation and continue with other projects. ”
Durante el encuentro el equipo de investigación, encabezado por la líder del proyecto ARVAC e investigadora de la UNSAM y del CONICET, Juliana Cassataro, repasó algunos resultados del trabajo realizado en la fase 3 y subrayó que la vacuna “cumple el objetivo en cuanto a respuesta inmune contra las tres variantes probadas y eso vamos a presentar ante la ANMAT”.
The first Argentine vaccine against COVID-19 ARVAC Cecilia Grierson is the initial director of the National University of San Martín, CONICET and the Cassará Laboratory, with that of the I D i Agency, of the Ministry of Science, Generation and Innovation. Matrix and Health of the Nation, operating in conjunction with more than 20 public and personal establishments in the country.